Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate

Purpose: Measurements of objective response rates are critical to evaluate new glioma therapies. The hallmark metabolic alteration in gliomas with mutant isocitrate dehydrogenase (IDH) is the overproduction of oncometabolite 2-hydroxyglutarate (2HG), which plays a key role in malignant transformatio...

Full description

Bibliographic Details
Main Authors: Andronesi, O. C., Loebel, F., Bogner, W., Marjanska, M., Iafrate, A. J., Dietrich, J., Batchelor, T. T., Gerstner, E. R., Kaelin, W. G., Chi, A. S., Rosen, B. R., Cahill, D. P., Vander Heiden, Matthew G.
Other Authors: Koch Institute for Integrative Cancer Research at MIT
Format: Article
Published: American Association for Cancer Research (AACR) 2018
Online Access:http://hdl.handle.net/1721.1/116921
https://orcid.org/0000-0002-6702-4192

Internet

http://hdl.handle.net/1721.1/116921
https://orcid.org/0000-0002-6702-4192

Similar Items